Background Male breast cancer (BC) is rare, managed by extrapolation from female BC. The
International Male BC Program aims to better characterize and manage this disease. We …

It has become customary to extrapolate from the results of treatment trials for female
breastcancer and apply them to males with the disease. In the absence of results from …

Male breast cancer (MaBC) is a rare disease, accounting for less than 1% of malignancies in
men. For this reason, literature data on its clinicopathological characteristics are very …

Male breast cancer (MBC) is a rare disease. The few studies on MBC reported conflicting
data regarding survival outcomes compared to women. This study has two objectives: to …

The rapidly growing collection of diverse genome-scale data from multiple tumor types
sheds light on various aspects of the underlying tumor biology. With the objective to identify …

Objective We aimed to describe the differences in clinicopathological characteristics and
overall survival (OS) between male and female breast cancer patients, and to develop a …

Purpose The introduction of HER2-targeting antibody drug conjugates (ADCs) offers new
treatment options for female breast cancer patients (FBC) expressing low levels of HER2 …

Abstract Purpose Male Breast Cancer (MBC) remains a poor understood disease.
Prognostic factors are not well established and specific prognostic subgroups are warranted …

Male breast cancer comprises less than 1% of breast cancer diagnoses. Although estrogen
exposure has been causally linked to the development of female breast cancers, the …

Breast cancer is the most common cancer form in women and it has been extensively
studied on the molecular level. Male breast cancer (MBC), on the other hand, is rare and has …